<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=8707445" created="17/07/2006" creator="Junko Matsuura"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>8707445</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="cytokine-modulating_activity" sem="Other"><term id="T2" lex="cytokine" sem="Protein_family_or_group">Cytokine</term>-modulating activity</term> of <term id="T3" lex="tepoxalin" sem="Organic_compound_other">tepoxalin</term>, a new potential <term id="T4" lex="antirheumatic" sem="Other">antirheumatic</term>.</sentence>
<event KT="Investigation" id="E1">
<type class="Regulation"/>
<theme idref="T2"/>
<cause idref="T3"/>
<clue>Cytokine-<clueType>modulating activity</clueType> <linkCause>of</linkCause> tepoxalin, a new potential antirheumatic.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term id="T5" lex="tepoxalin" sem="Organic_compound_other">Tepoxalin</term> is a new dual <term id="T6" lex="cyclooxygenase/5-lipoxygenase_anti-inflammatory_compound" sem="Organic_compound_other">cyclooxygenase/5-lipoxygenase anti-inflammatory compound</term> currently under clinical investigation.</sentence>
<sentence id="S3">It has been shown to possess <term id="T7" lex="anti-inflammatory_activity" sem="Other">anti-<term id="A1" sem="Other">inflammatory activity</term></term> in a variety of <term id="T8" lex="animal_model" sem="Multicellular_organism_natural">animal models</term> and more recently to inhibit <term id="T9" lex="IL-2_induced_signal_transduction" sem="Other"><term id="T10" lex="IL-2" sem="Protein_molecule">IL-2</term> induced <term id="A2" sem="Other">signal transduction</term></term>.</sentence>
<event KT="Analysis" Source="Other" id="E2">
<type class="Negative_regulation"/>
<theme idref="A1"/>
<cause idref="T5"/>
<clue><corefCause>It</corefCause> <clueSource>has been</clueSource> <clueKT>shown</clueKT> to possess <clueType>anti</clueType>-inflammatory activity <clueLoc>in a variety of animal models</clueLoc> and more recently to inhibit IL-2 induced signal transduction.</clue>
</event>
<event KT="Other" id="E3">
<type class="Positive_regulation"/>
<theme idref="A2"/>
<cause idref="T10"/>
<clue>It has been shown to possess anti-inflammatory activity in a variety of animal models and more recently to inhibit IL-2 <clueType>induced</clueType> signal transduction.</clue>
</event>
<event KT="Analysis" Source="Other" id="E4">
<type class="Negative_regulation"/>
<theme idref="E3"/>
<cause idref="T5"/>
<clue>It has been <clueKT>shown</clueKT> to possess anti-inflammatory activity in a variety of animal models and <clueSource>more recently</clueSource> to <clueType>inhibit</clueType> IL-2 induced signal transduction.</clue>
</event>
<sentence id="S4">The current study was conducted to evaluate the <term id="T11" lex="cytokine_modulating_activity" sem="Other"><term id="T12" lex="cytokine" sem="Protein_family_or_group">cytokine</term> modulating activity</term> of <term id="T13" lex="tepoxalin" sem="Organic_compound_other">tepoxalin</term> and the role of <term id="T14" lex="iron" sem="Element">iron</term> in these effects.</sentence>
<event KT="Investigation" id="E5" uncertainty="doubtful">
<type class="Regulation"/>
<theme idref="T12"/>
<cause idref="T13"/>
<clue>The current study was conducted <clueKT>to evaluate</clueKT> the cytokine <clueType>modulating activity</clueType> <linkCause>of</linkCause> tepoxalin and the role of iron in these effects.</clue>
</event>
<event KT="Investigation" id="E6" uncertainty="doubtful">
<type class="Regulation"/>
<theme idref="E5"/>
<cause idref="T14"/>
<clue>The current study was conducted <clueKT>to evaluate</clueKT> the cytokine modulating activity of tepoxalin and the <clueType>role</clueType> <linkCause>of</linkCause> iron <linkTheme>in</linkTheme> <corefTheme>these effects</corefTheme>.</clue>
</event>
<sentence id="S5">In <term id="T15" lex="human_peripheral_blood_mononuclear_cell" sem="Cell_natural">human peripheral blood mononuclear cells</term> (<term id="T16" lex="PBMC" sem="Cell_natural">PBMC</term>) stimulated with <term id="T17" lex="OKT3/PMA" sem="Organic_compound_other"><term id="A3" sem="Protein_family_or_group">OKT3</term>/<term id="A4" sem="Organic_compound_other">PMA</term></term>, <term id="T18" lex="tepoxalin" sem="Organic_compound_other">tepoxalin</term> inhibited <term id="T19" lex="lymphocyte" sem="Cell_natural">lymphocyte</term> proliferation with an <term id="T20" lex="IC50" sem="Other">IC50</term> of 6 microM.</sentence>
<event KT="Other" id="E7">
<type class="Cellular_physiological_process"/>
<theme idref="T19"/>
<clue>In human peripheral blood mononuclear cells (PBMC) stimulated with OKT3/PMA, tepoxalin inhibited lymphocyte <clueType>proliferation</clueType> with an IC50 of 6 microM.</clue>
</event>
<event id="E8">
<type class="Negative_regulation"/>
<theme idref="E7"/>
<cause idref="T18"/>
<clue><clueLoc>In human peripheral blood mononuclear cells (PBMC) stimulated with OKT3/PMA</clueLoc>, tepoxalin <clueType>inhibited</clueType> lymphocyte proliferation with an IC50 of 6 microM.</clue>
</event>
<event id="E9">
<type class="Physiological_process"/>
<theme idref="T16"/>
<cause idref="A3"/>
<clue>In human peripheral blood mononuclear cells (PBMC) <clueType>stimulated</clueType> <linkCause>with</linkCause> OKT3/PMA, tepoxalin inhibited lymphocyte proliferation with an IC50 of 6 microM.</clue>
</event>
<event id="E10">
<type class="Physiological_process"/>
<theme idref="T16"/>
<cause idref="A4"/>
<clue>In human peripheral blood mononuclear cells (PBMC) <clueType>stimulated</clueType> <linkCause>with</linkCause> OKT3/PMA, tepoxalin inhibited lymphocyte proliferation with an IC50 of 6 microM.</clue>
</event>
<sentence id="S6">Additionally, it inhibited the production of <term id="T21" lex="LTB4" sem="Protein_molecule">LTB4</term> (IC50 = 0.5 microM) and the <term id="T22" lex="cytokine" sem="Protein_family_or_group">cytokines</term> <term id="T23" lex="IL-2" sem="Protein_molecule">IL-2</term>, <term id="T24" lex="IL-6" sem="Protein_molecule">IL-6</term> and <term id="T25" lex="TNF_alpha" sem="Protein_molecule">TNF alpha</term> (IC50 = 10-12 microM).</sentence>
<event KT="Other" id="E11">
<type class="Gene_expression"/>
<theme idref="T21"/>
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event KT="Other" id="E12">
<type class="Gene_expression"/>
<theme idref="T23"/>
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event KT="Other" id="E13">
<type class="Gene_expression"/>
<theme idref="T24"/>
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event KT="Other" id="E14">
<type class="Gene_expression"/>
<theme idref="T25"/>
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E15">
<type class="Negative_regulation"/>
<theme idref="E11"/>
<cause idref="T18"/>
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E16">
<type class="Negative_regulation"/>
<theme idref="E12"/>
<cause idref="T18"/>
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E17">
<type class="Negative_regulation"/>
<theme idref="E13"/>
<cause idref="T18"/>
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E18">
<type class="Negative_regulation"/>
<theme idref="E14"/>
<cause idref="T18"/>
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<sentence id="S7"><term id="T26" lex="cytotoxicity" sem="Other">Cytotoxicity</term> was not demonstrated at these concentrations.</sentence>
<sentence id="S8">Add-back experiments with either <term id="T27" lex="cytokine" sem="Protein_family_or_group">cytokines</term> (<term id="T28" lex="IL-2" sem="Protein_molecule">IL-2</term> or <term id="T29" lex="IL-6" sem="Protein_molecule">IL-6</term>), <term id="T30" lex="LTB4" sem="Protein_molecule">LTB4</term> or <term id="A6" sem="Organic_compound_other">conditioned media</term> failed to restore the proliferative response in the presence of <term id="T31" lex="tepoxalin" sem="Organic_compound_other">tepoxalin</term>.</sentence>
<event Polarity="Negative" assertion="non-exist" id="E19">
<type class="Negative_regulation"/>
<theme idref="E8"/>
<cause idref="T28"/>
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType><cluePolarity>failed</cluePolarity> to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment></event>
<event Polarity="Negative" assertion="non-exist" id="E20">
<type class="Negative_regulation"/>
<theme idref="E8"/>
<cause idref="T29"/>
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType><cluePolarity>failed</cluePolarity> to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment></event>
<event Polarity="Negative" assertion="non-exist" id="E21">
<type class="Negative_regulation"/>
<theme idref="E8"/>
<cause idref="T30"/>
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType><cluePolarity>failed</cluePolarity> to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment></event>
<event Polarity="Negative" assertion="non-exist" id="E22">
<type class="Negative_regulation"/>
<theme idref="E8"/>
<cause idref="A6"/>
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType><cluePolarity>failed</cluePolarity> to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment></event>
<sentence id="S9">However, the concurrent addition of <term id="T32" lex="iron" sem="Element">iron</term> (in the form of <cons id="T33" lex="(OR ferrous_chloride ferric_chloride)" sem="(OR Inorganic_compound Inorganic_compound)"><frag id="F1">ferrous</frag> or <frag id="F2">ferric</frag> <frag id="F3">chloride</frag></cons> and other <term id="T34" lex="iron_salt" sem="Inorganic_compound"><term id="T35" lex="iron" sem="Element">iron</term> salts</term>) reversed the inhibition of <term id="A7" sem="Other">proliferation</term> caused by <term id="T36" lex="tepoxalin" sem="Organic_compound_other">tepoxalin</term>.</sentence>
<event KT="Other" id="E23">
<type class="Negative_regulation"/>
<theme idref="A7"/>
<cause idref="T36"/>
<clue>However, the concurrent addition of iron (in the form of ferrous or ferric chloride and other iron salts) reversed the <clueType>inhibition</clueType> <linkTheme>of</linkTheme> proliferation caused <linkCause>by</linkCause> tepoxalin.</clue>
</event>
<event id="E24">
<type class="Negative_regulation"/>
<theme idref="E23"/>
<cause idref="T32"/>
<clue>However, the concurrent addition of iron (in the form of ferrous or ferric chloride and other iron salts) <clueType>reversed</clueType> the inhibition of proliferation caused by tepoxalin.</clue>
</event>
<sentence id="S10"><term id="T37" lex="tepoxalin" sem="Organic_compound_other">Tepoxalin</term> also inhibits the activation of <term id="T38" lex="NF_kappa_B" sem="Protein_molecule">NF kappa B</term>, a <term id="T39" lex="transcription_factor" sem="Protein_family_or_group">transcription factor</term> which acts on several <term id="T40" lex="cytokine_gene" sem="DNA_family_or_group">cytokine genes</term>.</sentence>
<event KT="Other" id="E25">
<type class="Positive_regulation"/>
<theme idref="T38"/>
<clue>Tepoxalin also inhibits the <clueType>activation</clueType> <linkTheme>of</linkTheme> NF kappa B, a transcription factor which acts on several cytokine genes.</clue>
</event>
<event id="E26">
<type class="Negative_regulation"/>
<theme idref="E25"/>
<cause idref="T37"/>
<clue>Tepoxalin also <clueType>inhibits</clueType> the activation of NF kappa B, a transcription factor which acts on several cytokine genes.</clue>
</event>
<event KT="Fact" id="E27">
<type class="Regulation"/>
<theme idref="T40"/>
<cause idref="T38"/>
<clue>Tepoxalin also inhibits the activation of NF kappa B, a transcription factor which <clueType>acts</clueType> <linkTheme>on</linkTheme> several cytokine genes.</clue>
</event>
<sentence id="S11"><term id="T41" lex="tepoxalin" sem="Organic_compound_other">Tepoxalin</term>&apos;s effect on <term id="T42" lex="NF_kappa_B" sem="Protein_molecule">NF kappa B</term> is also reversed by the addition of <term id="T43" lex="iron_salt" sem="Inorganic_compound"><term id="T44" lex="iron" sem="Element">iron</term> salts</term>.</sentence>
<event KT="Other" id="E28">
<type class="Regulation"/>
<theme idref="T42"/>
<cause idref="T41"/>
<clue>Tepoxalin&apos;s <clueType>effect</clueType> <linkTheme>on</linkTheme> NF kappa B is also reversed by the addition of iron salts.</clue>
</event>
<event id="E29">
<type class="Negative_regulation"/>
<theme idref="E28"/>
<cause idref="T43"/>
<clue>Tepoxalin&apos;s effect on NF kappa B is also <clueType>reversed</clueType> <linkCause>by</linkCause> the addition of iron salts.</clue>
</event>
<sentence id="S12">These data suggest that the action of <term id="T45" lex="tepoxalin" sem="Organic_compound_other">tepoxalin</term> to inhibit <term id="T46" lex="proliferation" sem="Other">proliferation</term> in <term id="T47" lex="PBMC" sem="Cell_natural">PBMC</term> may be at least in part due to its ability to reduce the amount of available <term id="T48" lex="iron" sem="Element">iron</term> resulting in decreased activation of <term id="T49" lex="NF_kappa_B" sem="Protein_molecule">NF kappa B</term> and subsequent <term id="T50" lex="inhibition" sem="Other">inhibition</term> of <term id="T51" lex="cytokine_production" sem="Other"><term id="T52" lex="cytokine" sem="Protein_family_or_group">cytokine</term> production</term>.</sentence>
<event KT="Other" id="E61">
<type class="Cellular_physiological_process"/>
<theme idref="T47"/>
<clue>These data suggest that the action of tepoxalin to inhibit <clueType>proliferation</clueType> <linkTheme>in</linkTheme> PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event KT="Other" id="E30">
<type class="Negative_regulation"/>
<theme idref="E61"/>
<cause idref="T45"/>
<clue>These data suggest that the action of tepoxalin to <clueType>inhibit</clueType> proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event CL="L2" KT="Analysis" id="E31">
<type class="Negative_regulation"/>
<theme idref="T48"/>
<cause idref="T45"/>
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its <clueKT><clueCL>ability to</clueCL></clueKT> <clueType>reduce</clueType> the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event KT="Other" id="E33">
<type class="Positive_regulation"/>
<theme idref="T49"/>
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased <clueType>activation</clueType> <linkTheme>of</linkTheme> NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event KT="Other" id="E34" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E33"/>
<cause idref="E31"/>
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in <clueType>decreased</clueType> activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event KT="Other" id="E35">
<type class="Gene_expression"/>
<theme idref="T52"/>
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine <clueType>production</clueType>.</clue>
</event>
<event KT="Other" id="E36" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E35"/>
<cause idref="E34"/>
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent <clueType>inhibition</clueType> <linkTheme>of</linkTheme> cytokine production.</clue>
</event>
<event CL="L1" KT="Analysis" id="E62" uncertainty="probable">
<type class="Positive_regulation"/>
<theme idref="E30"/>
<cause idref="E36"/>
<clue>These data <clueKT>suggest</clueKT> that the action of tepoxalin to inhibit proliferation in PBMC <clueCL>may</clueCL> be at least in part <clueType>due</clueType> <linkTheme>to</linkTheme> its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
